How Does Nexletol Lower Cholesterol?
Nexletol (bempedoic acid) reduces LDL cholesterol by inhibiting ATP citrate lyase, an enzyme in the cholesterol synthesis pathway in the liver. This lowers LDL-C by 17-28% as monotherapy and up to 40% when combined with statins or ezetimibe in clinical trials.[1][2]
Who Benefits Most from Nexletol?
Patients with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C reduction but cannot tolerate statins due to muscle pain or other side effects. It's FDA-approved for these groups, either alone or with other therapies.[1]
What Do Cardiovascular Outcome Studies Show?
The CLEAR Outcomes trial (14,000+ patients) found Nexletol reduced major adverse cardiovascular events by 13% (composite of CV death, non-fatal MI, non-fatal stroke, or coronary revascularization) over 40 months, compared to placebo. Benefits were consistent across statin-intolerant patients and those on low-dose statins.[2][3]
How Does It Compare to Statins?
Unlike statins, Nexletol avoids muscle-related side effects because it doesn't enter muscle cells—only liver cells. It provides additive LDL-C lowering (15-25% extra) when added to maximally tolerated statins, making it a non-statin option for high-risk patients.[1][4]
What About Uric Acid and Other Effects?
Nexletol can raise uric acid levels, increasing gout risk in susceptible patients (use with xanthine oxidase inhibitors if needed). It has neutral effects on glucose and hemoglobin A1c, unlike some statins.[1][2]
When Does the Patent Expire?
U.S. patents on bempedoic acid extend to at least 2029, with some formulation patents to 2039; generics unlikely before then per DrugPatentWatch.com.[5]
[1] Nexletol Prescribing Information, Esperion Therapeutics, 2023. https://www.nexletol.com/hcp
[2] Nissen et al., NEJM 2023; CLEAR Outcomes trial. https://www.nejm.org/doi/full/10.1056/NEJMoa2215024
[3] FDA Approval Summary, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf
[4] Ray et al., NEJM 2019; CLEAR Harmony trial. https://www.nejm.org/doi/full/10.1056/NEJMoa1803916
[5] DrugPatentWatch.com, Bempedoic Acid patents. https://www.drugpatentwatch.com/p/tradename/NEXLETOL